1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The impact of Wnt pathway alterations including RNF43, GNAS, CTNNB1, and APC on prognosis and potential therapeutic vulnerability in pancreatic adenocarcinoma (PDAC)
    Meeting Abstract

    Takebe, N.; Blais, E. M.; Huynh, J.; Thach, D.; de Arbeloa, P. M.; Matrisian, L. M.; Petricoin, E.; Pishvaian, M. J.; Chung, V.; Boland, P. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Precision Promise (PrP) Bayesian platform trial for metastatic pancreatic cancer (mPDAC): Results of the first experimental arm, SM-88 as second line therapy
    Meeting Abstract

    Oberstein, P. E.; Wang-Gillam, A.; Varghese, A. M.; Ko, A. H.; Hendifar, A. E.; Ocean, A. J.; McGlothlin, A.; Graves, T.; Berry, S. M.; Detry, M. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Kinetics of CA19-9 decline in a randomized phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracial/leucovorin (NALIRIFOX) or nab-paclitaxel plus gemcitabine (GEM + NABP) in patients who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas (NAPOLI 3)
    Meeting Abstract

    Chandana, S. R.; Wainberg, Z. A.; Melisi, D.; Macarulla, T.; Pazo Cid, R. A.; De La Fouchardiere, C.; Dean, A. P.; Kiss, I.; Lee, W. J.; Goetze, T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Real-world analysis of patients with advanced gastrointestinal (GI) cancers harboring inactivating TSC1 and TSC2 alterations using the Foundation Medicine genomic database
    Meeting Abstract

    Deming, D. A.; Palma, N. A.; Navarro, W. H.; Iyer, G.; Kwiatkowski, D. J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • BNT321, a novel monoclonal antibody targeting sialyl Lewis A: Phase 1 monotherapy and combination with mFOLFIRINOX in patients with advanced CA19-9 expressing cancers
    Meeting Abstract

    O'Reilly, E. M.; Bauer, T. M.; Borazanci, E. H.; Pelster, M.; Varghese, A. M.; Park, W.; Patel, M. R.; Jameson, G. S.; Larsen, M.; Chin, K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Postoperative complications following neoadjuvant therapy and surgery in a phase 2 borderline resectable pancreatic cancer clinical trial (alliance A021501)
    Meeting Abstract

    Snyder, R. A.; Zemla, T. J.; Shi, Q.; Segovia, D. I.; Ahmad, S.; O'Reilly, E. M.; Herman, J. M.; Katz, M. H. G.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • ARC-8: Phase 1/1b randomized study of quemliclustat + gemcitabine/nab-paclitaxel ± zimberelimab in patients with treatment-naive metastatic pancreatic adenocarcinoma
    Meeting Abstract

    Wainberg, Z. A.; Manji, G. A.; Bahary, N.; Ulahannan, S. V.; Pant, S.; Uboha, N. V.; Oberstein, P. E.; Lu, L. H.; Scott, J. R.; Wu, W.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Salvage hepatic artery infusion chemotherapy after first-line systemic failure in patients with unresectable cholangiocarcinoma
    Meeting Abstract

    Nasar, N.; Armstrong, M.; Chou, J. F.; Gonen, M.; Soares, K.; Balachandran, V. P.; Drebin, J. A.; Kingham, T. P.; Wei, A. C. C.; D'Angelica, M. I.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Extrahepatic cholangiocarcinoma: Genomic variables associated with anatomical location and outcome
    Meeting Abstract

    Preston, W. A.; Drill, E. N.; Boerner, T.; Harding, J. J.; Cercek, A.; O'Reilly, E. M.; Abou-Alfa, G. K.; Park, W.; Balachandran, V. P.; Drebin, J. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • PROOF 301: Results of an early discontinued randomized phase 3 trial of the oral FGFR inhibitor infigratinib vs. gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma (CCA) with an FGFR2 gene fusion/rearrangement
    Meeting Abstract

    Abou-Alfa, G. K.; Borbath, I.; Roychowdhury, S.; Goyal, L.; Lamarca, A.; Macarulla, T.; Shroff, R. T.; Oh, D. Y.; Javle, M. M.; Tamas, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save